Atopic Dermatitis: Global Drug Forecast and Market Analysis to 2027

2018-11-24
Price :
Published : Nov-2018
No. of Pages : 108

Atopic Dermatitis: Global Drug Forecast and Market Analysis to 2027

Summary

Atopic Dermatitis is a widespread chronic inflammatory skin condition that can affect patients of all ages and is the result of a complex interplay of environmental, immunological, genetic, and pharmacologic factors. The atopic dermatitis market has historically remained stagnant and the pipeline for drugs in late-stage development was lacking, but recent developments have reignited interest in the treatment of the disease, especially as the estimated drug-treated population may grow to 24,000,000 people over the next decade.

In March 2017, Regeneron/Sanofi gained approval for Dupixent (dupilumab), the first-in-class interleukin (IL)-4 receptor inhibitor that has set a new gold standard in the treatment of atopic dermatitis. Moreover, a highly competitive and genericized topical market has pushed other pharmaceutical companies to develop their own systemic treatments, with a new class of therapies in development, Janus kinase (JAK) inhibitors, two of which have already been granted Breakthrough Therapy designation by the FDA. As a result, the atopic dermatitis market is set to become much more dynamic, with widening appreciation that atopic dermatitis is a highly variable disease and that not every patient will react in the same way to the same therapy. With existing unmet needs in the topical landscape for treatments that do not have side effects and for better understanding the pathophysiology and etiology of the disease, atopic dermatitis represents an attractive dermatology sector for drug developers. In turn, this will fuel commercial interest in this market.

GlobalData estimates that sales of drugs in the atopic dermatitis market were approximately $6.4B in 2017 in the 7MM. The US was the largest market, with approximately $5.1B in drug sales, which represented 80% of the total atopic dermatitis market. The 5EU market contributed $1.1B in sales and Japan contributed sales of $202M in 2017.

Global sales in the atopic dermatitis market are expected to grow to $18.3B by 2027, at a Compound Annual Growth Rate (CAGR) of 11.1% from 2017-2027. GlobalData forecasts the US to grow to $13.6B (74.5% of global sales), the 5EU to grow to $4B (21.7% of global sales), and Japan to grow to $693M (3.8% of global sales) over the next 10 years.

Key Questions Answered

– The projected entry of pipeline agents such as the Interleukin inhibitors and the JAK inhibitors during the forecast period is expected to spur intense growth within the atopic dermatitis market. How do products compete against each other? Which of these drugs will have the highest peak sales, and why?
– Key Opinion Leaders (KOLs) interviewed by GlobalData have indicated that there are considerably high unmet needs within the atopic dermatitis indication. What are the main unmet needs in this market? How can the pharmaceutical industry address these needs? To what degree will the therapies under development fulfill these unmet needs?
– The atopic dermatitis market is likely to remain a dynamic, growing space throughout the forecast period and beyond. Which companies are set to be major players in atopic dermatitis during the forecast period?

Scope

– Overview of atopic dermatitis including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
– Annualized atopic dermatitis therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2017 and forecast for ten years to 2027.
– Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the atopic dermatitis therapeutics market.
– Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
– Analysis of the current and future market competition in the global atopic dermatitis therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to –
– Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
– Develop business strategies by understanding the trends shaping and driving the global atopic dermatitis therapeutics market.
– Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global atopic dermatitis therapeutics market in future.
– Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
– Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
– Track drug sales in the global atopic dermatitis therapeutics market from 2017-2027.
– Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Filed in: Pharmaceutical, Therapeutics
Publisher : GlobalData
More Reports
Title Price Buy Now

Allergic Diseases: Pipeline Offers Novel Approaches to Treat Increasingly Prevalent Conditions, with Strong Presence of Cytokine Mediators Among First-in-Class Products

Allergic Diseases: Pipeline Offers Novel Approaches to Treat Increasingly Prevalent Conditions, with Strong Presence of Cytokine Mediators Among First-in-Class Products Summary An allergy or allergic disease is a condition that arises from an adverse reaction to an exogenous antigen, a substance that invokes an immunological response. These conditions are extremely common. The number of people diagnosed with allergic diseases is rising rapidly on a global scale, which is attributable to factors such as population growth and increased urbanization and pollution. In addition, for a minority of these patients, allergic reactions can be severe, debilitating, or even life-threatening. Despite this high disease burden, treatment options are limited for many conditions and patients often recei......
$6995

Digital Therapeutics and Their Impact on Healthcare

Digital Therapeutics and Their Impact on Healthcare Summary Due to increasing levels in healthcare spending combined with declining R&D returns, digital therapeutics (DTx) represent a new way of treatment in which digital systems are used as regulatory?approved, to treat medical conditions as prescribed therapeutic interventions. There is a growing number of DTx developed on the market today as well as pipeline products in development following internationally-recognized, quality, design and manufacturing standards. DTx will provide a new approach to treatment and disease management in which patients have the possibility to learn more about their conditions and treatment options and this will lead to manage their own health and disease conditions. This report provides an overview of cur......
$7995

Pharmaceutical & Healthcare Quarterly Deals Analysis M&A and Investment Trends – Q1 2019

Pharmaceutical & Healthcare Quarterly Deals Analysis M&A and Investment Trends - Q1 2019 Summary GlobalData's "Pharmaceutical & Healthcare Quarterly Deals Analysis M&A and Investment Trends - Q1 2019", report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in Q1 2019. The report portrays detailed comparative data on the number of deals and their value in the last five quarters, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information o......
$1500

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Italy

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Italy Summary GlobalData, the industry analysis specialist, has released its latest report, "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Italy". The report is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in Italy. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, reimbursement landscape and healthcare infrastructure of Italy. Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets. It is built using data and information sourced from proprietary databases, secondary research, and in-house analysis by ......
$1995

Partnerships, Licensing, Investments and M&A Deals and Trends for 2018 in Pharmaceuticals

Partnerships, Licensing, Investments and M&A Deals and Trends for 2018 in Pharmaceuticals Summary GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for 2018 in Pharmaceuticals", report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in 2018. The report portrays detailed comparative data on the number of deals and their value in the last five years, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on th......
$3500

Dermatophytosis Global Clinical Trials Review, H1, 2019

Dermatophytosis Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Dermatophytosis Global Clinical Trials Review, H1, 2019" provides an overview of Dermatophytosis clinical trials scenario. This report provides top line data relating to the clinical trials on Dermatophytosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. ......
$2500

Dysgeusia (Taste Disorders) Global Clinical Trials Review, H1, 2019

Dysgeusia (Taste Disorders) Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Dysgeusia (Taste Disorders) Global Clinical Trials Review, H1, 2019" provides an overview of Dysgeusia (Taste Disorders) clinical trials scenario. This report provides top line data relating to the clinical trials on Dysgeusia (Taste Disorders). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary dat......
$2500

Diabetic Neuropathy Global Clinical Trials Review, H1, 2019

Diabetic Neuropathy Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Diabetic Neuropathy Global Clinical Trials Review, H1, 2019" provides an overview of Diabetic Neuropathy clinical trials scenario. This report provides top line data relating to the clinical trials on Diabetic Neuropathy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical t......
$2500

Ectopic Pregnancy (Tubal Pregnancy) Global Clinical Trials Review, H1, 2019

Ectopic Pregnancy (Tubal Pregnancy) Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Ectopic Pregnancy (Tubal Pregnancy) Global Clinical Trials Review, H1, 2019" provides an overview of Ectopic Pregnancy (Tubal Pregnancy) clinical trials scenario. This report provides top line data relating to the clinical trials on Ectopic Pregnancy (Tubal Pregnancy). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated us......
$2500

Drug Addiction Global Clinical Trials Review, H1, 2019

Drug Addiction Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Drug Addiction Global Clinical Trials Review, H1, 2019" provides an overview of Drug Addiction clinical trials scenario. This report provides top line data relating to the clinical trials on Drug Addiction. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clin......
$2500
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy